Skip to content

A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease

Mobility Outcomes in Post-Pulmonary Embolic Disease (MOPED): A Pilot Feasibility Prospective Randomized Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06695247
Enrollment
100
Registered
2024-11-19
Start date
2025-07-14
Completion date
2026-12-01
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Brief summary

The purpose of this study is to develop a unique structure and delivery of home-based exercise through multidisciplinary expertise of cardiovascular medicine specialists and cardiac physiologists using an Interactive Care Plan.

Interventions

OTHERExercise Training

Patients will be recommended to exercise 3 days/week, 20 minutes per session, for 12 weeks using personalized intervention determined by a consultation with a clinical exercise physiologist (CEP)

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

Acute intermediate-risk PE, defined as: * Intraluminal filling defect in segmental or larger vessels on computed tomography pulmonary angiography or high-probability ventilation/perfusion scan AND * Evidence of right ventricular enlargement by computed tomography (RV to LV ratio \>1) or echocardiography; and/or right ventricular dysfunction by transthoracic echocardiography. These imaging characteristics must be in the setting of acute PE rather than explained by a prior chronic condition. Acute high-risk PE, defined as: * Intraluminal filling defect in segmental or larger vessels on computed tomography pulmonary angiography or high-probability ventilation/perfusion scan AND * Evidence of right ventricular enlargement by computed tomography (RV to LV ratio \>1) or echocardiography; and/or right ventricular dysfunction by transthoracic echocardiography. These imaging characteristics must be in the setting of acute PE rather than explained by a prior chronic condition; AND * Hypotension (systolic blood pressure \< 90 mm Hg sustained for more than 15 minutes; or requiring vasopressors) or cardiogenic shock due to acute pulmonary embolism.

Exclusion criteria

* Inability to ambulate independently, which is necessary to perform 6MWD (may be self-reported or as deemed by physical therapy during inpatient evaluation). * If patient requires supplemental oxygen during ambulation, this does not exclude patient from participation and will be noted during eCRF. * Prior history of pulmonary embolism * History of CTEPH or pulmonary arterial hypertension * Unable to read a questionnaire in English * Unable to return for baseline, 3- or 6-month follow-up visit * Pregnancy-associated pulmonary embolism * Life expectancy \<1 year based on comorbidities * Unable/unwilling to provide informed written consent

Design outcomes

Primary

MeasureTime frameDescription
Change in physical capacity from baselineBaseline, 3 Months, 6 MonthsPhysical capacity will be determined by 6-minute walk distance (6MWD)

Secondary

MeasureTime frameDescription
Change in Pulmonary Embolism-specific quality of life (PEmb-QOL) outcome measures from baselineBaseline, 3 Months, 6 MonthsThe Pulmonary Embolism-specific quality of life questionnaire assesses 6 quality of life dimensions in individuals with history of PE: frequency of symptoms, intensity of symptoms, activities of daily living limitations, social limitations, emotional distress, and work-related problems. Higher scores indicate worse quality of life.
Change in general Short Form 36 (SF-36) quality of life outcome measures from baselineBaseline, 3 Months, 6 MonthsThe Short Form 36 (SF-36) questionnaire assesses 8 quality of life dimensions: physical activity limitations, social activities limitations, activities of daily living physical limitations, bodily pain, general mental health, activities of daily living emotional limitations, vitality, and general health perceptions. Higher scores indicate better quality of life.
Number of StepsBaseline, 3 Months, 6 MonthsNumber of Steps will be determined by fitbit tracking with Fitabase.

Countries

United States

Contacts

CONTACTStan Henkin, M.D.
Henkin.Stanislav@mayo.edu507-284-8612
PRINCIPAL_INVESTIGATORStan Henkin, M.D.

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026